Patent 12123003 was granted and assigned to Checkmate Pharmaceuticals on October, 2024 by the United States Patent and Trademark Office.
The present disclosure relates to, inter alia, RNA molecules (e.g., RNA hairpin agonists) that bind to and agonize RIG-I-like receptors (RLRs), and to use of the molecules in methods for treating, or ameliorating one or more symptoms of, a disorder (e.g., cancer).